Sanofi SA
SNY47.800USD
-0.620-1.28%
終値 06/25, 16:00（ET）15分遅れの株価
119.84B時価総額
19.80直近12ヶ月PER
詳細情報 Sanofi SA 企業名
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
企業情報
企業コードSNY
会社名Sanofi SA
上場日Jul 01, 2002
設立日1994
最高経営責任者「CEO」Mr. Paul Hudson, Ph.D.
従業員数84587
証券種類Depository Receipt
決算期末Jul 01
本社所在地46 Avenue de la Grande Armee
都市PARIS
証券取引所NASDAQ Global Select Consolidated
国France
郵便番号75017
電話番号33153774000
ウェブサイトhttps://www.sanofi.com/
企業コードSNY
上場日Jul 01, 2002
設立日1994
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Barbara Lavernos
Ms. Barbara Lavernos
Director
Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Independent Director
Independent Director
--
--
Mr. Emile Voest, M.D., Ph.D.
Mr. Emile Voest, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Olivier Charmeil
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
--
--
Dr. Antoine Yver, M.D.
Dr. Antoine Yver, M.D.
Independent Director
Independent Director
--
--
Ms. Julie Van Ongevalle
Ms. Julie Van Ongevalle
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
--
--
Ms. Fabienne Lecorvaisier
Ms. Fabienne Lecorvaisier
Independent Director
Independent Director
--
--
Ms. Audrey Duval Derveloy
Ms. Audrey Duval Derveloy
Executive Vice President - Corporate Affairs, Member of the Executive Committee
Executive Vice President - Corporate Affairs, Member of the Executive Committee
--
--
Ms. Clotilde Delbos
Ms. Clotilde Delbos
Independent Director
Independent Director
--
--
Mr. Frederic Oudea
Mr. Frederic Oudea
Independent Chairman of the Board
Independent Chairman of the Board
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Barbara Lavernos
Ms. Barbara Lavernos
Director
Director
--
--
Dr. Jean-Paul Kress, M.D.
Dr. Jean-Paul Kress, M.D.
Independent Director
Independent Director
--
--
Mr. Emile Voest, M.D., Ph.D.
Mr. Emile Voest, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Olivier Charmeil
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
--
--
Dr. Antoine Yver, M.D.
Dr. Antoine Yver, M.D.
Independent Director
Independent Director
--
--
Ms. Julie Van Ongevalle
Ms. Julie Van Ongevalle
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
--
--
収益内訳
通貨: USD更新時刻: Sun, Apr 6
通貨: USD更新時刻: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
事業別USD
会社名
収益
比率
Dupixent
14.14B
31.82%
Polio / Pertrussis / Hib
2.96B
6.67%
Meningitis, Travel and endemic vaccines
1.82B
4.10%
Booster vaccines
1.42B
3.20%
Alltuviio
737.64M
1.66%
Other
23.34B
52.54%
地域別USD
会社名
収益
比率
United States
21.62B
48.65%
Rest of the World (Japan, South Korea, Canada, Australia, New Zealand)
13.05B
29.38%
Europe excl. France
7.80B
17.56%
France
1.96B
4.42%
事業別
地域別
事業別USD
会社名
収益
比率
Dupixent
14.14B
31.82%
Polio / Pertrussis / Hib
2.96B
6.67%
Meningitis, Travel and endemic vaccines
1.82B
4.10%
Booster vaccines
1.42B
3.20%
Alltuviio
737.64M
1.66%
Other
23.34B
52.54%
株主
更新時刻: Fri, May 16
更新時刻: Fri, May 16
株主統計
種類
株主統計
株主統計
比率
Dodge & Cox
2.90%
Fisher Investments
0.54%
Invesco Advisers, Inc.
0.45%
T. Rowe Price Associates, Inc.
0.44%
Capital World Investors
0.33%
Other
95.35%
株主統計
株主統計
比率
Dodge & Cox
2.90%
Fisher Investments
0.54%
Invesco Advisers, Inc.
0.45%
T. Rowe Price Associates, Inc.
0.44%
Capital World Investors
0.33%
Other
95.35%
種類
株主統計
比率
Investment Advisor/Hedge Fund
5.32%
Investment Advisor
4.18%
Research Firm
0.71%
Hedge Fund
0.19%
Bank and Trust
0.07%
Pension Fund
0.02%
Family Office
0.01%
Other
89.50%
機関投資家保有株
更新時刻: Sun, Jan 19
更新時刻: Sun, Jan 19
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q1
1263
279.29M
11.05%
-8.17M
2024Q4
1263
270.44M
10.70%
-30.67M
2024Q3
1239
286.03M
11.43%
-5.72M
2024Q2
1248
275.46M
11.01%
-5.50M
2024Q1
1232
261.25M
10.33%
-7.62M
2023Q4
1213
251.25M
9.93%
-18.33M
2023Q3
1178
256.18M
10.15%
-15.97M
2023Q2
1173
257.65M
10.20%
-26.92M
2023Q1
1174
268.83M
10.66%
-6.19M
2022Q4
1167
264.16M
10.47%
-6.09M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Dodge & Cox
75.22M
2.98%
-1.08M
-1.41%
Dec 31, 2024
Fisher Investments
12.51M
0.5%
-848.08K
-6.35%
Dec 31, 2024
Invesco Advisers, Inc.
11.37M
0.45%
+303.99K
+2.75%
Dec 31, 2024
T. Rowe Price Associates, Inc.
10.84M
0.43%
+5.09M
+88.50%
Dec 31, 2024
Managed Account Advisors LLC
7.74M
0.31%
-611.48K
-7.32%
Dec 31, 2024
Barrow Hanley Global Investors
7.70M
0.3%
-140.54K
-1.79%
Dec 31, 2024
Fidelity Management & Research Company LLC
4.95M
0.2%
-3.65M
-42.49%
Dec 31, 2024
Wellington Management Company, LLP
4.48M
0.18%
-166.02K
-3.57%
Dec 31, 2024
Boston Partners
5.40M
0.21%
+2.50M
+86.38%
Dec 31, 2024
詳細を見る
関連ETF
更新時刻: Fri, Jun 6
更新時刻: Fri, Jun 6
銘柄名
比率
VanEck Pharmaceutical ETF
3.68%
Simplify Health Care ETF
3.54%
Putnam Focused Large Cap Value ETF
2.59%
Brandes US Value ETF
2.34%
Invesco International Dividend Achievers ETF
2.12%
Pacer Global Cash Cows Dividend ETF
2.01%
Altrius Global Dividend ETF
1.98%
Invesco Nasdaq Biotechnology ETF
1.47%
ProShares Ultra Nasdaq Biotechnology
1.4%
T Rowe Price Equity Income ETF
1.19%
詳細を見る
VanEck Pharmaceutical ETF
比率3.68%
Simplify Health Care ETF
比率3.54%
Putnam Focused Large Cap Value ETF
比率2.59%
Brandes US Value ETF
比率2.34%
Invesco International Dividend Achievers ETF
比率2.12%
Pacer Global Cash Cows Dividend ETF
比率2.01%
Altrius Global Dividend ETF
比率1.98%
Invesco Nasdaq Biotechnology ETF
比率1.47%
ProShares Ultra Nasdaq Biotechnology
比率1.4%
T Rowe Price Equity Income ETF
比率1.19%
配当金
過去5年間の配当金総支払額は
23.51B
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
Mar 26, 2024
SNY.NB Final Cash Dividend of gross USD 2.036908 paid on Jun 06, 2024 going ex on May 09, 2024
May 10, 2024
Jun 06, 2024
May 09, 2024
Feb 15, 2023
SNY.NB Final Cash Dividend of gross USD 1.900085 paid on Jun 23, 2023 going ex on May 30, 2023
May 31, 2023
Jun 23, 2023
May 30, 2023
Apr 20, 2022
SNY.NB Final Cash Dividend of gross USD 1.74684 paid on May 31, 2022 going ex on May 04, 2022
May 05, 2022
May 31, 2022
May 04, 2022
Mar 24, 2021
SNY.NB Final Cash Dividend of gross USD 1.928784 paid on May 26, 2021 going ex on May 03, 2021
May 04, 2021
May 26, 2021
May 03, 2021
Mar 05, 2020
SNY.NB Final Cash Dividend of gross USD 1.699399 paid on May 26, 2020 going ex on Apr 30, 2020
May 01, 2020
May 26, 2020
Apr 30, 2020
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
